^
Association details:
| Biomarker: | KMT2D mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1639 - Correlation of KMT2C/D loss-of-function mutations with PD-L1 expression and response to immune checkpoint inhibitors in solid tumors
Published date:
03/10/2021
Excerpt:
We classified the patients into two groups: KMT2C/D LOF (any truncating mutation) and non-LOF….Furthermore, the median OS was also higher in the LOF group compared with the non-LOF group in NSCLC (undefined vs 12 months, P = 0.05)….Furthermore, KMT2C/D LOF mutations were also associated with better response to ICIs in colorectal cancer and NSCLC...
